Prostatype Genomics (Sweden) Performance
| PROGEN Stock | SEK 5.45 0.10 1.80% |
The company holds a Beta of 0.16, which implies not very significant fluctuations relative to the market. As returns on the market increase, Prostatype Genomics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Prostatype Genomics is expected to be smaller as well. At this point, Prostatype Genomics has a negative expected return of -0.33%. Please make sure to check Prostatype Genomics' skewness, as well as the relationship between the rate of daily change and price action indicator , to decide if Prostatype Genomics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Prostatype Genomics AB has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 15.9 M | |
| Total Cashflows From Investing Activities | -2.5 M |
Prostatype |
Prostatype Genomics Relative Risk vs. Return Landscape
If you would invest 805.00 in Prostatype Genomics AB on December 1, 2024 and sell it today you would lose (260.00) from holding Prostatype Genomics AB or give up 32.3% of portfolio value over 90 days. Prostatype Genomics AB is generating negative expected returns and assumes 8.3161% volatility on return distribution over the 90 days horizon. Simply put, 74% of stocks are less volatile than Prostatype, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Prostatype Genomics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Prostatype Genomics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Prostatype Genomics AB, and traders can use it to determine the average amount a Prostatype Genomics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0391
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PROGEN |
Estimated Market Risk
| 8.32 actual daily | 74 74% of assets are less volatile |
Expected Return
| -0.33 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Prostatype Genomics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Prostatype Genomics by adding Prostatype Genomics to a well-diversified portfolio.
Prostatype Genomics Fundamentals Growth
Prostatype Stock prices reflect investors' perceptions of the future prospects and financial health of Prostatype Genomics, and Prostatype Genomics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Prostatype Stock performance.
| Return On Equity | -0.7 | |||
| Return On Asset | -0.39 | |||
| Operating Margin | (23.61) % | |||
| Current Valuation | 20.62 M | |||
| Shares Outstanding | 22.86 M | |||
| Price To Book | 1.14 X | |||
| Price To Sales | 34.59 X | |||
| Revenue | 10 K | |||
| EBITDA | (15.46 M) | |||
| Cash And Equivalents | 7.66 M | |||
| Cash Per Share | 0.58 X | |||
| Total Debt | 866.67 K | |||
| Debt To Equity | 0.07 % | |||
| Book Value Per Share | 1.50 X | |||
| Cash Flow From Operations | (16.08 M) | |||
| Earnings Per Share | (1.22) X | |||
| Total Asset | 40.2 M | |||
About Prostatype Genomics Performance
By analyzing Prostatype Genomics' fundamental ratios, stakeholders can gain valuable insights into Prostatype Genomics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Prostatype Genomics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Prostatype Genomics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests. The company was founded in 2007 and is based in Solna, Sweden. Prostatype Genomics is traded on Stockholm Stock Exchange in Sweden.Things to note about Prostatype Genomics performance evaluation
Checking the ongoing alerts about Prostatype Genomics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Prostatype Genomics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Prostatype Genomics generated a negative expected return over the last 90 days | |
| Prostatype Genomics has high historical volatility and very poor performance | |
| The company reported the revenue of 10 K. Net Loss for the year was (15.63 M) with loss before overhead, payroll, taxes, and interest of (5.98 M). | |
| Prostatype Genomics AB has accumulated about 7.66 M in cash with (16.08 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.58. |
- Analyzing Prostatype Genomics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Prostatype Genomics' stock is overvalued or undervalued compared to its peers.
- Examining Prostatype Genomics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Prostatype Genomics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Prostatype Genomics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Prostatype Genomics' stock. These opinions can provide insight into Prostatype Genomics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Prostatype Stock analysis
When running Prostatype Genomics' price analysis, check to measure Prostatype Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Prostatype Genomics is operating at the current time. Most of Prostatype Genomics' value examination focuses on studying past and present price action to predict the probability of Prostatype Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Prostatype Genomics' price. Additionally, you may evaluate how the addition of Prostatype Genomics to your portfolios can decrease your overall portfolio volatility.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |